...
首页> 外文期刊>Turkish Journal of Emergency Medicine >Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis
【24h】

Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis

机译:Nivolumab,一种新的免疫调节药物,一种新的不良反应;肾上腺危机

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Owing to the advancements in medicine, new information is obtained regarding cancer, new antineoplastic agents are developed. Frequent use of these new pharmacological agents emergency physicians to be vigilant about their side effects. We present a case of adrenal crisis in a patient with non-small cell lung cancer (NSCLC), caused by an immunomodulatory drug; nivolumab. While adverse events are related to other immunomodulatory drugs have been reported in literature, our case is the first nivolumab-related adrenal failure to be reported. A patient with lung cancer presented to the emergency room(ER) with nausea and vomiting. Hyponatremia, hyperkalemia, persistent hypoglycemia led to the diagnosis of adrenal crisis. Having direct effect on the immune system, these drugs were claimed to be highly reliable. However, there is no reliable data on the side effect profile of these agents. It should be kept in mind that life-threatening auto-immune reactions may occur.
机译:由于医学的进步,获得了有关癌症的新信息,开发了新的抗肿瘤药。急诊医师经常使用这些新的药理剂以防备其副作用。我们介绍了由免疫调节药物引起的非小细胞肺癌(NSCLC)患者的肾上腺危机病例; nivolumab。尽管文献中已经报道了与其他免疫调节药物相关的不良事件,但我们的病例是首次报道的与尼古鲁单抗相关的肾上腺衰竭。一名肺癌患者因恶心和呕吐而出现在急诊室。低钠血症,高钾血症,持续性低血糖导致诊断为肾上腺危机。这些药物对免疫系统有直接影响,据称是高度可靠的。但是,在这些药物的副作用方面没有可靠的数据。请记住,可能发生危及生命的自身免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号